Evgen Pharma PLC
LSE:EVG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CHTC Helon Co Ltd
SZSE:000677
|
CN |
|
ams OSRAM AG
OTC:AMSSY
|
AT |
|
Local Bounti Corp
NYSE:LOCL
|
US |
|
G
|
Gansu Golden Glass Technologies Co Ltd
SZSE:300093
|
CN |
Evgen Pharma PLC
Total Equity
Evgen Pharma PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evgen Pharma PLC
LSE:EVG
|
Total Equity
£3.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Equity
$610m
|
CAGR 3-Years
31%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Equity
£381m
|
CAGR 3-Years
11%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Equity
-$52.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Equity
£504m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Equity
£91.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
24%
|
|
Evgen Pharma PLC
Glance View
Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.
See Also
What is Evgen Pharma PLC's Total Equity?
Total Equity
3.9m
GBP
Based on the financial report for Sep 30, 2023, Evgen Pharma PLC's Total Equity amounts to 3.9m GBP.
What is Evgen Pharma PLC's Total Equity growth rate?
Total Equity CAGR 5Y
13%
Over the last year, the Total Equity growth was -45%. The average annual Total Equity growth rates for Evgen Pharma PLC have been 15% over the past three years , 13% over the past five years .
